Rational Antibiotic Use in Office Practice
- PMID: 40601222
- DOI: 10.1007/s12098-025-05631-6
Rational Antibiotic Use in Office Practice
Abstract
Antimicrobial resistance (AMR) is emerging as a global health threat. Microbial resistance emerged almost simultaneously with the discovery of penicillin and has kept pace with almost every new antibiotic molecule. With the increasing AMR and declining initiative for discovery of newer antibiotics from research and pharmacologic industry, humanity may be entering a post-antibiotic era of inability to treat any infection. As per the global estimate, AMR ranks as high as the third leading cause of death. India being the largest consumer of antibiotics faces a huge burden of AMR. ICMR data reveals that methicillin resistant Staphylococcus aureus (MRSA) prevalence is in more than half the specimens and among the Gram negative organisms, carbapenem resistance is seen in nearly 50% in E. coli and klebsiella in 2023.The contributory factors for AMR are patient, prescriber, system and environment related, as well as the rampant use of antibiotics in animal husbandry, aquaculture and biocides. Government of India is making efforts to restrict AMR through a National Action Plan by strategies such as enhancing knowledge about AMR, improving Antimicrobial Stewardship, monitoring antibiotic use and increasing coordination among stakeholders under 'One Health' initiative. To promote rational antibiotic choice and prevent AMR, WHO has categorised antibiotics as per the level of need as Access, Watch and Reserve (AWaRe) antibiotics. Robust National and WHO guidelines are available to treat all the infections encountered in office practice.
Keywords: AWaRe; Antimicrobial resistance; Antimicrobial stewardship; National action plan; Office practice; One Health.
© 2025. The Author(s), under exclusive licence to Dr. K C Chaudhuri Foundation.
Conflict of interest statement
Declarations. Conflict of Interest: None. Guarantor: Ramachandran Padmanabhan will act as guarantor for this manuscript.
References
-
- Chai G, Governale L, McMahon AW, Trinidad JP, Staffa J, Murphy D. Trends of outpatient prescription drug utilization in US children, 2002–2010. Pediatrics. 2012;130:23–31. - PubMed
-
- Special Eurobarometer 478: Antimicrobial Resistance (in the EU) [Internet]. European Commission, Directorate-General for Communication. 2018. Available at: http://data.europa.eu/88u/dataset/S2190_90_1_478_ENG . Accessed June 2, 2025.
-
- Institute for Health Metrics and Evaluation (IHME). India Profile. Seattle, WA: IHME, University of Washington. 2024. Available at: https://www.healthdata.org/sites/default/files/2023-09/India.pdf . Accessed November 24, 2024.
-
- Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis. Lancet. 2022;399:629–55.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials